{Reference Type}: Journal Article
{Title}: Doing more with less: surgical results of pediatric posterior fossa tumors from a single center in Latin America.
{Author}: Formentin C;de Souza Rodrigues Dos Santos L;Matias LG;de Castro Oliveira DL;Sabba MF;Joaquim AF;Tedeschi H;Ghizoni E;
{Journal}: Childs Nerv Syst
{Volume}: 40
{Issue}: 9
{Year}: 2024 Sep 12
{Factor}: 1.532
{DOI}: 10.1007/s00381-024-06539-w
{Abstract}: <B>OBJECTIVE: </B>We aim to report the epidemiology, surgical outcomes, and survival rates of pediatric patients with posterior fossa tumors in a large single-center case series.<BR><B>METHODS: </B>A retrospective analysis was conducted on pediatric patients who underwent surgical treatment for posterior fossa tumors between January 2011 and January 2019.<BR><B>RESULTS: </B>A total of 135 pediatric patients, with an average age of 7.5 years at diagnosis and a mean follow-up of 35.7 months, were included in the study. Most tumors were located within the midline, with ventriculomegaly observed in 71.4% of the patients. Pilocytic astrocytomas encompassed the majority of tumors (34.1%), followed by medulloblastomas (27.4%) and ependymomas (11.8%). Gross total resection (GTR) was achieved in 71.8% of the patients, with a recurrence rate of 20%. Surgical complications were observed in 25.9% of the patients. GTR significantly impacted 5-year overall survival (OS) and 4-year progression-free survival (PFS) in patients with posterior fossa tumors. Patients who underwent GTR had a 5-year OS of 89.7%, compared to 72.7% for near-total resection and 70.8% for subtotal resection. The 4-year PFS for patients who underwent GTR was 82.5%, whereas it was 63.6% for patients who underwent near-total resection and 54.2% for patients who underwent subtotal resection.<BR><B>CONCLUSIONS: </B>Surgical resection remains the main treatment for pediatric posterior fossa tumors, and higher resection rates are linked to better survival outcomes. Despite limited resources for molecular diagnosis, our institution has demonstrated that a specialized neurooncological center with a high surgical volume can still achieve favorable survival outcomes for these patients.